ES2178393T3 - Utilizacion de analogos del vip en la prevencion y el tratamiento de las lesiones cerebrales en el neonato humano. - Google Patents

Utilizacion de analogos del vip en la prevencion y el tratamiento de las lesiones cerebrales en el neonato humano.

Info

Publication number
ES2178393T3
ES2178393T3 ES99907701T ES99907701T ES2178393T3 ES 2178393 T3 ES2178393 T3 ES 2178393T3 ES 99907701 T ES99907701 T ES 99907701T ES 99907701 T ES99907701 T ES 99907701T ES 2178393 T3 ES2178393 T3 ES 2178393T3
Authority
ES
Spain
Prior art keywords
lys
vip
prevention
treatment
nle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99907701T
Other languages
English (en)
Inventor
Pierre Gressens
Patrick Robberecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP filed Critical Assistance Publique Hopitaux de Paris APHP
Application granted granted Critical
Publication of ES2178393T3 publication Critical patent/ES2178393T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

Utilización de un análogo del VIP seleccionado en el grupo constituido por los análogos cíclicos del VIP y los derivados del VIP no cíclicos de 31 aminoácidos que incluyen, en posición N-terminal, un grupo N-acetil, y Glu en posición 8 (Glu8), Lys en posición 12 (Lys12), norleucina en posición 17 (Nle17), Ala en posición 19 (Ala19), X1 en posición 21, X2 en posición 25, Leu en posición 26 (Leu26), Lys en posición 27 y 28 (Lys27 y Lys28), Gly en posición 29 y 30 (Gly29 y Gly30) y Thr en posición 31 (Thr31), donde X1 representa Lys (Lys21) o Nle (Nle21) y X2 representa Asp (Asp23 o Asn (Asn25), para la obtención de un medicamento para la prevención o el tratamiento de las lesiones cerebrales del feto, el neonato prematuro o llegado a término, o el lactante humano.
ES99907701T 1998-03-13 1999-03-12 Utilizacion de analogos del vip en la prevencion y el tratamiento de las lesiones cerebrales en el neonato humano. Expired - Lifetime ES2178393T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9803125A FR2775902B1 (fr) 1998-03-13 1998-03-13 Utilisation d'analogues du vip dans la prevention et le traitement des lesions cerebrales du nouveau-ne humain

Publications (1)

Publication Number Publication Date
ES2178393T3 true ES2178393T3 (es) 2002-12-16

Family

ID=9524030

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99907701T Expired - Lifetime ES2178393T3 (es) 1998-03-13 1999-03-12 Utilizacion de analogos del vip en la prevencion y el tratamiento de las lesiones cerebrales en el neonato humano.

Country Status (7)

Country Link
EP (1) EP1061945B1 (es)
AT (1) ATE218363T1 (es)
CA (1) CA2322018A1 (es)
DE (1) DE69901690T2 (es)
ES (1) ES2178393T3 (es)
FR (1) FR2775902B1 (es)
WO (1) WO1999047159A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972319B1 (en) 1999-09-28 2005-12-06 Bayer Pharmaceuticals Corporation Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
CA2379604A1 (en) * 1999-09-28 2001-04-05 Bayer Corporation Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use
US7507714B2 (en) 2000-09-27 2009-03-24 Bayer Corporation Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
EP2187929A2 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of a peptide as a therapeutic agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105061A (en) * 1993-03-16 2000-11-21 Yeda Res & Dev Pharmaceutical compositions for the treatment of neurodegenerative diseases comprising VIP analogues and fragments thereof
CN1186355C (zh) * 1996-02-09 2005-01-26 霍夫曼-拉罗奇有限公司 血管活性肠肽类似物的合成

Also Published As

Publication number Publication date
WO1999047159A1 (fr) 1999-09-23
DE69901690D1 (de) 2002-07-11
EP1061945A1 (fr) 2000-12-27
ATE218363T1 (de) 2002-06-15
CA2322018A1 (fr) 1999-09-23
EP1061945B1 (fr) 2002-06-05
FR2775902A1 (fr) 1999-09-17
FR2775902B1 (fr) 2001-05-11
DE69901690T2 (de) 2003-02-13

Similar Documents

Publication Publication Date Title
ATE266043T1 (de) Peptidanaloge des menschlichen basischen myelinproteins
HUP0100928A2 (hu) Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
DE69931793D1 (de) Verfahren für die behandlung der multiplen sklerose mittels peptidanalogen des menschlichen basischen myelinproteins
HUP0003349A2 (hu) Mellékpajzsmirigy-hormon peptidanalógok, ezeket hatóanyagként tartalmazó gyógyászati készítmények és alkalmazásuk
BR9707036A (pt) Análogos de il-10 sintéticos.
ATE192037T1 (de) Verwendung von arginin als immunstimulator
MXPA02000465A (es) Derivados ciclopeptidicos como inhibidores de la integrina alfav beta6.
DE69725850D1 (de) Analoge des parathormons zur behandlung der osteoporose
ATE213499T1 (de) Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
DE69326849D1 (de) Verwendung von humanem Atrio-natriuretischem Peptid zur Herstellung eines Medikaments zur Behandlung des Atemunwohlseinsyndroms bei Erwachsenen
NO952336L (no) Insulin analoger
ES2178393T3 (es) Utilizacion de analogos del vip en la prevencion y el tratamiento de las lesiones cerebrales en el neonato humano.
DE69630583D1 (de) Peptide, bronchodilator und den blutstrom verbesserndes mittel
DE59306654D1 (de) Cyclopeptide
ATE98962T1 (de) Menschliche rhinoviruspeptide.
KR960000248A (ko) 골대사 질환 치료제
ATE183652T1 (de) Synthetische peptide für die behandlung von myasthenia gravis
DE69433817D1 (de) Lineare und cyklische peptide zur behandlung oder vorbeugung der crohn'schen krankheit und/oder der ulzerativen kolitis
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
ATE121626T1 (de) Verwendung von 20(r)-22-oxa-vitamin d analoge zur herstellung eines medikaments für die behandlung des altershaut.
DE60038310D1 (de) Menschliche antithrombin-varianten
ATE27822T1 (de) Hexapeptid, verfahren zur herstellung und pharmazeutische zusammensetzungen hieraus.
WO2002083729A3 (en) Polypeptides derived from amyloid precursor peptide (app) and their uses
PT100299A (pt) Analogo de hirudina, metodo para a sua producao e anti-coagulante contendo-o, e vector de secrecao , microorganismos transformados com o referido vector e metodo para a producao de produtos a partir dos referidos microorganismos